Torilis japonica extract, a new potential EMT suppressor agent by regulation of EGFR signaling pathways

Kim,Guen  Tae; Lee,Se  Hee; Kim,Young  Min

doi:10.3892/ijo.2014.2546

Torilis japonica extract, a new potential EMT suppressor agent by regulation of EGFR signaling pathways

Authors:
- Guen Tae Kim
- Se Hee Lee
- Young Min Kim
View Affiliations

Affiliations: Department of Biological Sciences, College of Life Science and Nano Technology, Hannam University, Yuseong-gu, Daejeon 305-811, Republic of Korea
Published online on: July 17, 2014 https://doi.org/10.3892/ijo.2014.2546
Pages: 1673-1679

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abnormal metastasis of carcinoma is associated with the loss of epithelial features and the acquisition of a mesenchymal phenotype. The stimulation of cells with epidermal growth factor (EGF) resulted in morphological changes and induced epithelial-mesenchymal transition (EMT). EGF stimulation resulted in increased mobility along with upregulated actin polarization related proteins, E-cadherin regulators and the mesenchymal markers. Treatment with Torilis japonica extract (TJE) along with stimulation by EGF prevented changes in cell morphology, mobility, expression of actin polarization proteins and EMT markers. Using specific inhibitors and siEGFR, it was demonstrated that TJE suppressed EMT through EGFR inactivation and regulation of its downstream signaling pathways. We suggest that TJE is a new potential reagent for EGFR-targeted therapy and anti-abnormal metastasis in MCF-7 breast cancer.

View Figures

View References

1	Hay ED: An overview of epithelia-mesenchymal transformation. Acta Anat. 154:8–20. 1995. View Article : Google Scholar : PubMed/NCBI
2	Kalluri R and Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 112:1776–1784. 2003. View Article : Google Scholar : PubMed/NCBI
3	Kalluri R and Weinberg RA: The basic of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
4	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transition in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
5	Acloque H, Adams MA, Fishwick K, Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 199:1438–1449. 2009. View Article : Google Scholar : PubMed/NCBI
6	Foroni C, Broggini M, Generali D and Damia G: Epithelial-mesenchymal transition and breast cancer: role, molecular emchanisms and clinical impact. Cancer Treat Rev. 38:689–697. 2012. View Article : Google Scholar : PubMed/NCBI
7	Moreno-Bueno G, Portillo F and Cano A: Transcriptional regulation of cell polarity in EMT and cancer. Oncogene. 27:6958–6969. 2008. View Article : Google Scholar : PubMed/NCBI
8	Klymkikowsky MW and Savagner P: Epithelial-mesenchymal transition: a cancer researcher’s conceptual friend and foe. Am J Pathol. 174:1588–1593. 2009.PubMed/NCBI
9	Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S and Auersperg N: Molecular patheways regulating EGF-induced epithelia-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol. 290:C1532–C1542. 2006. View Article : Google Scholar : PubMed/NCBI
10	Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washingtom MK, et al: TGF-β signaling in fibroblasts modulation the oncogenic potential of adjacent epithelia. Science. 6:848–851. 2004.
11	Suo Z, Risberg B, Karlsson MG, Villman K, Skovlund E and Nesland JM: The expression of EGFR family ligands in breast carcinoma. Int J Surg Pathol. 10:91–99. 2002. View Article : Google Scholar : PubMed/NCBI
12	Ramapul RS, Pinder SE, Wencyk PM, Nicholson RI, Blamey RW, Robertson JF and Ellis IO: Epidermal growth factor receptor status operable invasive cancer: is it of any prognostic value? Clin Cancer Res. 10:25782004.PubMed/NCBI
13	Sasaki T, Hiroki K and Yamashita Y: The role of epidermal growth factor receptor in cancer metastasis and microenviromental. Biomed Res Int. 2013:5463182013. View Article : Google Scholar : PubMed/NCBI
14	Nieto MA: The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 3:155–166. 2002. View Article : Google Scholar : PubMed/NCBI
15	Hajra KM, Chen SY and Fearon ER: The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62:1613–1618. 2002.PubMed/NCBI
16	Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Höfler H, et al: Differential expression of the epithelial-mesenchymal transition regulators Snail, SIP1, and twist in gastric cancer. Am J Pathol. 161:1881–1891. 2002. View Article : Google Scholar : PubMed/NCBI
17	Vandewalle C, Van Roy F and Berx G: The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci. 66:773–787. 2009. View Article : Google Scholar : PubMed/NCBI
18	Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, Tulachan SS, et al: N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res. 10:4125–4133. 2004. View Article : Google Scholar : PubMed/NCBI
19	Nijkamp MM, Span PN, Hoogsteen LJ, Van der Kogel AJ, Kaanders JH and Bussink J: Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol. 99:344–348. 2011. View Article : Google Scholar : PubMed/NCBI
20	Benz PM, Blume C, Seifert S, Wilhelm S, Waschke J, Schuh K, Gertler F, et al: Differential VASP phosphorylation controls remodeling of the actin cytoskeleton. J Cell Sci. 122:3954–3965. 2009. View Article : Google Scholar : PubMed/NCBI
21	Krause M, Dent EW, Bear JE, Loureiro JJ and Gertler FB: Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol. 19:541–564. 2003.
22	Harbeck B, Hüttelmaier S, Schluter K, Jockusch BM and Illenberger S: Phosphorylation of the vasodilator-stimulated phosphoprotein regulates its interaction with actin. J Biol Chem. 275:30817–30825. 2000. View Article : Google Scholar : PubMed/NCBI
23	He M, Cheng Y, Li W, Liu Q, Liu J, Huang J and Fu X: Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. BMC Cancer. 10:1702010. View Article : Google Scholar : PubMed/NCBI
24	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
25	Colditz GA, Sellers TA and Trapido E: Epidemiology - identifying cause and preventability of cancer? Nat Rev Cancer. 6:75–83. 2006. View Article : Google Scholar : PubMed/NCBI
26	Lee SH, Kim GT, Kim JI, Lim EG, Kim IS and Kim YM: The extract from Lysimachia foenum-graecum induce apoptosis in MCF-7 breast cancer cells. KSSB J. 28:303–309. 2013.
27	Pan SY, Zhou SF, Gao SH, Yu ZL, Zhang SF, Tang MK, Sun JN, et al: New perspectives on how to discover drugs from herbal medicines: CAM’s outstanding contribution to modern therapeutics. Evid Based Complement Alternat Med. 2013:62737582013.PubMed/NCBI
28	Shizhen Li: Ben Cao Gang Mu [Compendium of Materia Medica]. China: 1593
29	Zhongjing Zhang: Shang han Lun [Treatise on cold damage disorders]. China: pp. 220
30	Jones JL, Royall JE and Walker RA: E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma. Br J Cancer. 74:1237–1241. 1996. View Article : Google Scholar : PubMed/NCBI
31	Holz C, Niehr F, Boyko M, Hristozova T, Distel L, Budach V and Tinhofer I: Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells. Radiother Oncol. 101:158–164. 2011. View Article : Google Scholar : PubMed/NCBI
32	Cheng JC, Auersperg N and Leung PC: EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? PLoS One. 7:e340712012. View Article : Google Scholar : PubMed/NCBI
33	Vergara D, Valente CM, Tinelli A, Siciliano C, Lorusso V, Acierno R, Giovinazzo G, et al: Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal trasition in MCF-7 cells. Cancer Lett. 310:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
34	Jin Y, Iwata KK, Belldegrum A, Figlin R, Pantuck A, Zhang ZF, Lieberman R, et al: Effect of an epidermal growth factor receptor tyrosine kinase inhibitor in actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol Cancer Ther. 5:1754–1765. 2006. View Article : Google Scholar : PubMed/NCBI
35	Wallerand H, Cai Y, Wainberg ZA, Garraway I, Lascombe I, Nicolle G, Thiery JP, et al: Phospho-Akt pathway activation and inhibition depends on N-cadherin or phosphor-EGFR expression in invasive human bladder cancer cell lines. Urol Oncol. 28:180–188. 2010. View Article : Google Scholar : PubMed/NCBI
36	Weigelt B, Peterse JL and van’t Veer LJ: Breast cancer metastasis: markers and models. Nat Rev Cancer. 5:591–602. 2005. View Article : Google Scholar : PubMed/NCBI
37	Pinder SE, Ellis IO, Galea M, O’Rouke S, Blamey RW and Elston CW: Pathological prognostic factors in breast cancer. III Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopatology. 24:41–47. 1994. View Article : Google Scholar : PubMed/NCBI
38	de Boer M, van Dijck JA, Bult P, Borm GF and Tjan-Heijnen VC: Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst. 102:410–425. 2010.PubMed/NCBI